

Mosaique Balanced USD

Rothschild & Co WM Fund (SICAV SIF)

Cover: © Getty Images.
© 2023 Rothschild & Co
Wealth Management

This is not a promotion or solicitation of the Rothschild & Co WM SICAV SIF – Mosaique Balanced USD, which is not usually available to execution only or advisory clients. When certain criteria are met discretionary portfolios may hold the Fund, but only at Rothschild & Co's discretion.

Values: All data as at 31st March 2023. Sources of charts and tables: Rothschild & Co and Bloomberg, unless otherwise stated. Past performance is not indicative of future performance and investments and the income from them can fall as well as rise. Fund performance is shown in US dollars, after all fees, in total return, combining income and capital growth. Returns may increase or decrease as a result of currency fluctuations.

Please ensure you read the Important Information section at the end of this document.

Fund manager's review

Central banks increased interest rates further during the first quarter as they continued to tame inflation. Concern about the economic outlook and the possibility of recession was compounded by turmoil in the banking sector. Yet stock markets showed resilience by shrugging off much of the uncertainty and climbing higher over the period.

MARKET OVERVIEW

After a strong January, stock markets pared some of their gains as the prospect of higher interest rates and, more recently, concerns over the health of the banking system moved into focus. The collapse of Silicon Valley Bank and, in turn, the enforced acquisition of Credit Suisse by UBS, ignited concerns over financial contagion, with bank stock prices falling sharply. Whilst financials came under pressure, the global growth backdrop continued to look resilient and technology rebounded following a tough 2022, with the Nasdaq Composite posting its best start to the year since 2001.

PORTFOLIO PERFORMANCE

The first quarter of 2023 was a tale of reversal but ultimately ending in positive portfolio investment performance. Maintaining the positive trend from Q4 2022, the portfolio roared into the new year, built up by effervescent market sentiment. In February, there was a pullback in performance with sentiment swinging back, following renewed hawkish stance of central banks and a repricing of interest rates anticipations to the upside. In the meantime, inflation continued to see companies grow cautious with their profit margin forecasts. Nevertheless, a resilient March restored the positive performance, and we march on.

In Fixed Income, we continued our duration and credit exposure management over the quarter. Stronger economic data that were published in February in many developed markets led to higher moves in bond yields which we used to lengthen the portfolio duration. More on that in Portfolio Activity. The high volatility during March in the aftermath of the collapse of Silicon Valley Bank (SVB) and the directed takeover of

Credit Suisse (CS) by UBS – as displayed in higher volatility in both rates and spreads questioned the case for tighter monetary policies again but ended ultimately in spreads that returned to pre-SVB/CS news flow levels.

Within Equities, we kept a neutral positioning in the asset class. Stock picking was the main performance driver, where the financial exposed names contributed positively, undeterred by the collapse of SVB and near-death of CS. On the other hand, it was a difficult quarter for our healthcare names.

Our preference for companies that demonstrate high quality characteristics such as strong profitability and large size were a net positive. Also, in contrast to last year where the market preferred cheaply valued companies, this year the market pivoted and consequently the abovementioned quality characteristics and elements of growth within the portfolio were a boon to performance. We maintain our philosophy towards good quality business that have pricing power and can improve their competitive position within their industries during times of economic stress.

Among single stocks the financial names in the portfolio: American Express, Visa, and Morgan Stanley were good examples of winners this quarter with increases in the share price relative to their respective peers. Following the exogenous shocks to the financial sector, with SVB and CS, investors sought safety in more quality and consequently, these quality financial names prospered. LVMH (>20%) and Alibaba (>10%) both performed well on the back of strong consumer demand, chiefly boosted from a gradual improvement in China. Finally, ASML – a timely introduction in January – rose above 15% versus the market, reporting excellent results and an upbeat outlook for the current year.

Data sources: Rothschild & Co and Bloomberg

Holdings are subject to change without notice. This document does not constitute a personal recommendation or an offer or invitation to buy or sell securities or any other banking or investment product. Past performance is not indicative of future performance and investments and the income from them can fall as well as rise.

Fund manager's review (continued)

The laggards were United Health, Danaher, and Roche. The latter continued its decline from the previous quarter, falling a further c.10% due to mixed 2022 results and a rather soft outlook. Despite reporting pleasing fourth quarter earnings, both United Health and Danaher declined. We attribute this more to profit taking, as both remain on track for resilient organic growth and rising margins.

PORTFOLIO ACTIVITY

Several changes were made to the portfolio this quarter.

Starting with Equities, in January we introduced ASML to the portfolio to add some semiconductor exposure. The leading provider of semiconductor manufacturing equipment bounced back in from the wider semi-conductor sell off in the second half of 2022. Here, we saw an attractive entry point, with the stock at a reasonable valuation and a record backlog of new business. To balance the trade, we trimmed Apple.

Then in February, we took advantage of a strong market run to prune some Microsoft and Alphabet. Along with the reduction of Apple, we managed to reduce our investment bias toward mega-caps in the portfolio.

In March, we diversified our healthcare exposure by selling Roche and introducing Thermo Fisher to the portfolio. Thermo Fisher is one of the world's largest MedTech companies and a global leader in the life science segment. Over the last decade, the company grew significantly driven by a track record of M&A activity in accompaniment with a growing customer base (over 400'000 customers). We think Thermo Fisher has the potential to improve its business quality, end market exposure, pricing power and margins. Finally, we sold Bank of America. The bank benefitted strongly during early stages of the Fed's tightening cycle, but this effect typically dissipates towards the end of the cycle. We felt far enough through the tightening cycle to have reached the maximum benefit of holding the stock.

Elsewhere in Fixed Income, we completed the transition from the Muzinich Global Short Duration fund into the medium duration R-Co Conviction Credit fund. We decided to invest capital at higher yields, where we believe we can benefit from slightly lengthening the duration of the portfolio.

Fund performance

At the end of the first quarter 2023, the performance stood at 4.8% QTD and 4.8% YTD.

PERFORMANCE SINCE INCEPTION (%)*



* Data represents total returns of the investment strategy over the period from 7 April 2017 to 31 March 2023. The launch date of the Fund which implements this strategy was 7 April 2017.

PERFORMANCE TABLE (%)

	QTD	YTD	1 YEAR	3 YEARS	5 YEARS	SINCE INCEPTION
MOSAIQUE BALANCED USD X	4.8	4.8	-4.7	25.6	26.3	35.6

MONTHLY PERFORMANCE TABLE (%)

	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	YTD
2023	4.7	-2.7	2.9										4.8
2022	-3.6	-2.4	0.7	-5.6	0.0	-5.0	4.8	-2.8	-6.2	2.8	5.3	-1.9	-13.9
2021	-0.4	0.5	0.1	3.2	0.8	1.5	1.1	1.6	-2.7	3.0	-1.7	1.3	8.6
2020	0.6	-3.6	-8.9	6.8	3.1	2.6	4.2	4.4	-1.9	-1.2	5.7	1.9	13.2
2019	4.0	1.9	1.7	2.2	-2.1	3.2	0.5	-0.3	0.5	1.7	1.5	1.7	17.6

Portfolio holdings

The objective of the fund is to generate capital growth over time, while maintaining a broad diversification through liquid securities.


EQUITIES 48.1%		FIXED INCOME 39.0%	
North America 24.7%		Investment Grade 32.9%	
Microsoft	2.6%	Diversified USD Investment Grade Single Bonds*	30.5%
SPDR S&P U.S. Energy Select Sector UCITS ETF	2.4%	R-co Conviction Credit Euro Fund	2.4%
Apple	2.1%	High Yield 6.2%	
Visa	1.5%	Vontobel Emerging Markets Debt Fund	2.0%
Alphabet	1.5%	Muzinich Europeyield Fund USD-h	1.5%
Otis	1.4%	Vontobel Emerging Markets Corporate Bonds	1.3%
Linde	1.3%	iShares USD High Yield Corp Bond UCITS ETF	1.4%
Costco Wholesale Corp	1.2%		
Canadian National Railway	1.2%		
S&P Global	1.0%		
Danaher	1.0%		
Nike	1.0%		
United Health	1.0%		
Adobe	1.0%		
American Express	0.8%		
JPMorgan Chase & Co	0.8%		
Thermo Fisher	0.8%		
Amazon.com	0.8%		
Comcast	0.6%		
Morgan Stanley	0.6%		
Europe 6.5%		MULTI-ASSET & HYBRID INSTRUMENTS 6.6%	
iShares MSCI EMU ESG Screened UCITS ETF	1.4%	Structured Products (Yield) 6.6%	
ASML	1.2%	7.81% UBS Jersey (Exp.17.05.23) on FESX/ Nikkei225/S&P500/SMI	1.7%
Diageo	1.1%	Cert Morgan Stanley (Exp.02.08.23) on Nikkei225/ SMI/S&P500/ESTX50	1.6%
London Stock Exchange	1.1%	Cert Raiffeis Switzerland (Exp.02.10.23) on MSCI ESG Basket	1.6%
LVMH	1.1%	Dispersion Cert BNP Paribas Iss (Exp.14.04.23) on Equities	1.6%
Epiroc	0.7%	Structured Products (Hedging) <0.1%	
Emerging Markets 6.2%		Wts Goldman Sachs 16.06.2023 Put on MSCI World	<0.1%
Veritas Asian Fund	3.8%		
JPM Global Emerging Markets UCITS ETF ESG Screened	1.8%		
Alibaba	0.5%		
Global 8.1%		ALTERNATIVE STRATEGIES 2.6%	
LongRun Equity Fund	4.2%	Alternative Strategies 2.6%	
iShares MSCI ACWI UCITS ETF	2.3%	Atropos CatBond	1.7%
iShares MSCI World Health Care Sector ESG UCITS ETF	1.6%	One River Dynamic Convexity Fund	0.9%
Japan 2.6%		MONEY MARKET 1.6%	
MSCI Japan Socially Responsible UCITS ETF	2.0%	Money Market 1.6%	
SPDR MSCI Japan UCITS ETF	0.6%	USD Liquidity	1.6%
		COMMODITIES 2.2%	
		Gold 2.2%	
		Rothschild & Co Gold Fund	2.2%

Percentages may not sum to 100% due to rounding.


Fund allocation

The Fund invests in equities, equity-related securities, fixed income securities, alternative strategies, commodities and money market instruments.


FUND HOLDINGS BY ASSET CLASSES




FUND ALLOCATION BY CURRENCY



EQUITY ALLOCATION BY SECTOR



FIXED INCOME ALLOCATION BY CREDIT RATING



Percentages may not sum to 100% due to rounding. The above currency exposure is net of foreign exchange hedges. For the purposes of more accurately managing currency risk, where appropriate, we reflect the currency exposure of certain funds based on the underlying securities held within the fund, rather than the denomination of the fund.

Supporting information

ROTHSCHILD & CO WM FUND (SICAV SIF) – MOSAIQUE BALANCED USD

Legal structure	SICAV SIF
Objective	Long-term return on invested capital by investing in a roughly equal combination of bonds mainly denominated in USD and a well-diversified equity portfolio.
Launch date	7 April 2017
Fiscal year end	31 December
Domicile	Luxembourg
Management company	Rothschild & Co Investment Managers
Fund administrator	CACEIS Bank, Luxembourg
Depository bank	CACEIS Bank, Luxembourg
Inception date	7 April 2017
Liquidity	Daily (trading cut-off 15:00 CET)

Notes

At Rothschild & Co Wealth Management we offer an objective long-term perspective on investing, structuring and safeguarding assets, to preserve and grow our clients' wealth.

We provide a comprehensive range of services to some of the world's wealthiest and most successful families, entrepreneurs, foundations and charities.

In an environment where short-term thinking often dominates, our long-term perspective sets us apart. We believe preservation first is the right approach to managing wealth.



Important information

All performance data refers to share class Acc X.

Source: Rothschild & Co and Bloomberg

Sharpe ratio: Sharpe Ratio is the statistical measure of excess portfolio return over the risk-free rate relative to its standard deviation.

Annualized Volatility: Annualized Volatility is the measure of return dispersion for an asset over twelve month since inception.

Maximum Loss: This is the largest monthly drop in the portfolio's value during a given period. It is expressed as a percentage and reflects the fall in value during the time between the draw down peak (highest value) and the draw down valley (lowest value).

This document is issued by the Rothschild & Co WM SICAV SIF, a société anonyme incorporated under the laws of Luxembourg, on a strictly confidential basis to a limited number of potential investors, being "well informed investors" pursuant to the Luxembourg Law of February 13, 2007 relating to specialized investment funds, as amended (the "SIF Law"), who have indicated their potential interest for

the Rothschild & Co WM SICAV SIF. This document does not constitute a personal recommendation or an offer or invitation to buy or sell securities or any other banking or investment product.

Further information and risk warnings on this Fund or other share classes or sub-funds of the SICAV-SIF may be found in the issue document, in the articles of association, in the annual report of the SICAV-SIF. The SICAV-SIF is subject to Luxembourg tax law. This may affect your personal tax situation. The value of investments, and the income from them, can go down as well as up, and you may not recover the amount of your original investment. Past performance should not be taken as a guide to future performance. Where an investment involves exposure to a foreign currency, changes in rates of exchange may cause the value of the investment, and the income from it, to go up or down.

The Fund may not be available in all jurisdictions and in some jurisdictions it may be available on a limited basis only, due to local regulatory and legal requirements. This document is not directed to, nor intended for distribution or use by, any person or entity in any jurisdiction or country where the publication or availability of this document or such distribution or use would be contrary to local law or regulation.

© 2020 MSCI ESG Research LLC. Reproduced by Permission. Although Rothschild & Co. Bank AG's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for, or a component of, any financial instruments or products or indices. Further, none of the Information can in and of itself be used to determine which securities to buy or to sell or when to buy or to sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with the data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.